Key Highlights

  • Precision BioSciences (NASDAQ:DTIL) was quoted 17.49% higher at about USD 9.54 in trading on November 5, 2026, per published market data, with Volume 5.79 times its usual level.
  • The company priced an underwritten offering of about USD 125 million at USD 7.75 per share on November 5, 2026, with closing expected on or about November 6, 2026.
  • The deal covers 10,235,077 common shares plus pre-funded warrants for up to 5,893,964 shares, led by TD Cowen and Guggenheim Securities.
  • Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD, the company's hepatitis B and Duchenne muscular dystrophy gene-editing programs, plus general corporate purposes.

The Offering Behind the Headline

Precision BioSciences (NASDAQ:DTIL) announced on November 5, 2026 the pricing of an underwritten public offering of about USD 125 million before fees. The price was USD 7.75 per share for 10,235,077 common shares, with pre-funded warrants for up to 5,893,964 shares offered to certain investors at USD 7.749995, the share price less a USD 0.000005 exercise price. Closing is expected on or about November 6, 2026. TD Cowen and Guggenheim Securities are joint book-running managers. Participants included First Light Asset Management, MPM BioImpact, Bleichroeder, Lynx1 Capital Management, Readout Capital, Aberdeen Investments and Driehaus Capital Management. The shares were quoted 17.49% higher at about USD 9.54 in trading on November 5, 2026, per published market data, above the offering price.

How the Deal Works and Where the Money Goes

A pre-funded Warrant lets an investor pay almost the full price up front and exercise later for a nominal sum, which helps holders who want to stay under an ownership threshold. Both instruments add to the share count, so existing holders own a smaller slice. Simple arithmetic on the disclosed terms gives roughly 16.1 million shares and USD 125 million, which is close to half of the USD 266.51 million Market Value in published market data, so dilution is material. Proceeds will fund PBGENE-HBV and PBGENE-DMD, plus working capital. Published coverage says the company reported a third-quarter 2026 net loss of about USD 7.6 million on November 3, 2026, and that its hepatitis B candidate is advancing toward a Phase 2 stage, details of which should be read in the company filings.

Risks and What to Watch

Biotech shares of this size carry thin-liquidity and Reversal risk. A small number of trades can move the price, spreads can be wide and quoted moves can reverse, including after a large raise priced below the recent trading level. Clinical-stage gene editing carries trial, safety, Manufacturing and regulatory risks, and results from one study do not carry over to the next. Cash raised extends the runway but does not remove the need for further funding if development costs rise. The company has no positive earnings, so value rests on pipeline progress rather than profit. Investors will watch the closing of the offering, any further disclosure on the hepatitis B Phase 2 design and timing, and Duchenne program updates.

Where Things Stand

Precision BioSciences (NASDAQ:DTIL) is up 17.49% in the quoted session most plausibly because a fully subscribed USD 125 million raise from specialist healthcare funds removes near-term funding worry, even though it dilutes existing holders. The offering price of USD 7.75 sits below the quoted USD 9.54 level, which shows how fast sentiment can move. The quoted gain is intraday and can reverse. Next come the closing, development updates and the next quarterly report.